ClinicalTrials.Veeva

Menu

Study Evaluating the Tolerance and Safety of Enbrel (Etanercept) in Adults and Children

Wyeth logo

Wyeth

Status

Completed

Conditions

Rheumatoid Arthritis

Treatments

Drug: Enbrel (Etanercept)

Study type

Observational

Funder types

Industry

Identifiers

NCT00484809
0881A-101511

Details and patient eligibility

About

This postmarketing surveillance study will evaluate the safety profile of Enbrel (etanercept) in an Indian population. It will provide surveillance on a currently approved indication for Enbrel of reducing symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.

Sex

All

Ages

4+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Inclusion in this study will be as per the approved indications in the package insert.
  • Patients with moderately to severely active RA.
  • Children with JRA who have had an inadequate response to one or more DMARDs.

Exclusion criteria

  • Known hypersensitivity to etanercept or any of its components.

  • Known significant concurrent medical disease, including:

    • Congestive heart failure, uncontrolled angina pectoris, recent history of myocardial infarction
    • Cancer or history of cancer
    • Active infection
    • Sepsis or risk of sepsis
    • Active tuberculosis or a past history of tuberculosis
    • Pancytopenia
  • Females who are pregnant, breast feeding or at risk of pregnancy and not using a medically acceptable form of contraception.

  • Patients who are planning to undergo elective surgery during the study period.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems